Niagen Bioscience cites preclinical Nature Communications NR findings

Niagen Bioscience said an independent Nature Communications preclinical study identified CD38 as a driver of age-related NAD+ decline and reported that NR restored NAD+ and improved pregnancy outcomes in aged mice; the NR used was not Niagen’s product.